Joana Carvalho, PhD, managing science editor —

Joana holds a bachelor’s in biology, a Master of Science in evolutionary and developmental biology, and a PhD in biomedical sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — those that make up the lining of blood vessels — found in the umbilical cord of newborns. In addition to several research fellowships, she was awarded two Erasmus scholarships to conduct part of her studies in France.

Articles by Joana Carvalho

FDA Partially Rescinds Indications for BeneFIX and Ixinity

Owing to conflicting market exclusivity rights, the U.S. Food and Drug Administration (FDA) has partially rescinded its decision to approve BeneFIX and Ixinity for additional indications both therapies received last year for the treatment of hemophilia B, according to the National Hemophilia Foundation. Pfizer’s BeneFIX and…

Efanesoctocog Alfa on Fast Track for Hemophilia A

The U.S. Food and Drug Administration (FDA) has granted fast track designation to efanesoctocog alfa, an investigational factor VIII (FVIII) replacement therapy for treating hemophilia A, Sanofi, one of the therapy’s developers, announced in a press release. This designation is given to accelerate the development and review of…

Top 10 Hemophilia Stories of 2020

Hemophilia News Today brought you daily coverage in 2020 of important discoveries, treatment advancements, clinical trial findings, and other important events related to hemophilia. As we look forward to bringing you more news this year, we present here the 10 most-read stories of 2020, along with a summary of…